Reha-Baris Incesu, Simone Morra, Lukas Scheipner, Francesco Barletta, Andrea Baudo, Cristina Cano Garcia, Stefano Tappero, Mattia Luca Piccinelli, Zhe Tian, Fred Saad, Shahrokh F Shariat, Ottavio de Cobelli, Carlo Terrone, Felix K H Chun, Luca Carmignani, Alberto Briganti, Sascha Ahyai, Nicola Longo, Derya Tilki, Markus Graefen, Pierre I Karakiewicz
BACKGROUND: In 2021, the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium reported improved overall survival (OS) rates in a modern cohort of metastatic non-seminoma testis cancer patients within each of the IGCCCG prognosis groups (96% in good vs. 89% in intermediate vs. 67% in poor), compared to the previous IGCCCG publication (92% in good vs. 80% in intermediate vs. 48% in poor). We hypothesized that a similar survival improvement may apply to a contemporary North-American population-based cohort of non-seminoma testis cancer patients...
February 17, 2024: Japanese Journal of Clinical Oncology